Evidence map›Paper›PMID 37448563›Full record

ArticleiScience2023

Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.

Shinya Yamamoto, Seiya Yamayoshi, Mutsumi Ito, Yuko Sakai-Tagawa, Ichiro Nakachi, Rie Baba, Shigenobu Kamimoto, Takayuki Ogura, Shigehiro Hagiwara, Hideaki Kato and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Shinya YamamotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Mutsumi ItoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Yuko Sakai-TagawaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Ichiro NakachiPulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
Rie BabaPulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
Shigenobu KamimotoPulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
Takayuki OguraDepartment of Emergency and Intensive Care, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
Shigehiro HagiwaraDepartment of Clinical Laboratory, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
Hideaki KatoDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Yoshifumi UwaminoDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
Kazuma YagiDepartment of Pulmonary Medicine, Keiyu Hospital, Kanagawa 220-8521, Japan.
Norio SugayaDepartment of Pediatrics, Keiyu Hospital, Kanagawa 220-8521, Japan.
Hiroyuki NagaiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Makoto SaitoDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Eisuke AdachiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Michiko KogaDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Takeya TsutsumiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Calvin DuongDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Moe OkudaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Jurika MurakamiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Yuri FurusawaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Michiko UjieDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Hiroshi YotsuyanagiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Tokyo University of Science · JPSaiseikai Utsunomiya hospital · JPkeiyu Hospital · JPYokohama City University · JPKeio University · JPUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 has gradually acquired amino acid substitutions in its S protein that reduce the potency of neutralizing antibodies, leading to decreased vaccine efficacy. Here, we attempted to obtain mutant viruses by passaging SARS-CoV-2 in the presence of plasma samples from convalescent patients or vaccinees to determine which amino acid substitutions affect the antigenicity of SARS-CoV-2. Several amino acid substitutions in the S2 region, as well as the N-terminal domain (NTD) and receptor-binding domain (RBD), affected the neutralization potency of plasma samples collected from vaccinees, indicating that amino acid substitutions in the S2 region as well as those in the NTD and RBD affect neutralization by vaccine-induced antibodies. Furthermore, the neutralizing potency of vaccinee plasma samples against mutant viruses we obtained or circulating viruses differed among individuals. These findings suggest that genetic backgrounds of vaccinees influence the recognition of neutralizing epitopes.

Indexed as

ImmunologyVirology

Identifiers

PMID37448563
PMCPMC10290734
OpenAlexW4381950564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.